These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33826483)

  • 1. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.
    Sajid Jamal QM; Alharbi AH; Ahmad V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7960-7974. PubMed ID: 33826483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.
    Sharma P; Joshi T; Mathpal S; Joshi T; Pundir H; Chandra S; Tamta S
    J Biomol Struct Dyn; 2022 Apr; 40(6):2757-2768. PubMed ID: 33143552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding and inhibitory effect of ravidasvir on 3CL
    Bera K
    J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An
    Clemente CM; Freiberger MI; Ravetti S; Beltramo DM; Garro AG
    J Biomol Struct Dyn; 2022 Aug; 40(12):5653-5664. PubMed ID: 33459192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
    Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
    J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.
    Shode FO; Idowu ASK; Uhomoibhi OJ; Sabiu S
    J Biomol Struct Dyn; 2022 Sep; 40(14):6587-6602. PubMed ID: 33590806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
    J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biflavonoids from
    Lokhande K; Nawani N; K Venkateswara S; Pawar S
    J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
    Swain SS; Singh SR; Sahoo A; Hussain T; Pati S
    J Biomol Struct Dyn; 2022 Sep; 40(14):6463-6476. PubMed ID: 33583350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of phytoconstituents of
    Choudhary P; Singh T; Amod A; Singh S
    J Biomol Struct Dyn; 2023 Jun; 41(9):4106-4123. PubMed ID: 35467486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.